San Ramon, CA – February 6, 2020 – Bioventrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced it received renewal of the highest priority reimbursement in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System by achieving the NUB Status 1 designation from InEk, the German Institute for Hospital Remuneration.


San Ramon, CA, Nov. 19, 2019 -- BioVentrix, Inc., a privately-held company with a first-in-class, transcatheter-based structural heart device to treat heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation status for its Revivent TC™ Transcatheter Ventricular Enhancement System for heart failure.

San Ramon, CA, USA – Oct. 07, 2019 – BioVentrix, Inc. announced the first patient was enrolled and treated in the REVIVE-HF European study, a prospective multi-center, dual-arm randomized controlled study evaluating the treatment of ischemic cardiomyopathy induced heart failure with the Revivent TC System compared to Guideline-Directed Medical Therapy (GDMT) or drug treatment. 


BioVentrix is een particulier bedrijf op het gebied van medische hulpmiddelen dat te San Ramon, CA, in de Verenigde Staten is gevestigd.

Ons nieuws

Contact Us

© 2020 BioVentrix. Alle rechten voorbehouden. Powered by MedTech Momentum
Het Revivent TC ™ handelsmerk is een federaal geregistreerd handelsmerk dat eigendom is van BioVentrix. Elk ongeautoriseerd gebruik is uitdrukkelijk verboden.